Jan H.M. Schellens
1,477 works · 65,100 citations · h-index 115
Top works
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
- Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
- Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
- Photodynamic Therapy in Oncology
- Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
- A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918
- Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
- DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
- An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons
- Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
- Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.